Target Approaches
Transcription factors
Transcription factors (TFs) are pivotal in orchestrating gene expression, influencing cellular processes such as development, differentiation, and apoptosis. Despite the challenge of directly targeting TFs with small molecules due to their complex nature and lack of defined ligand-binding domains, recent advancements have opened new avenues for drug discovery.
Jubilant Biosys offers comprehensive services for TF drug discovery, including the development of innovative assays that enable the identification and validation of novel modulators. Our platform leverages cutting-edge strategies such as targeting specific DNA-binding domains, synthetic lethality approaches and utilizing proteolysis-targeting chimeras (PROTACs). Additionally, we employ indirect approaches like inhibiting protein-protein interactions, suppressing TF expression, and modulating post-translational modifications and TF-DNA interactions.
Our tailored approach to TF assay development, combined with high-throughput screening and structure-activity relationship (SAR) support, positions us at the forefront of unlocking the therapeutic potential of these historically “undruggable” targets. With a focus on precision and innovation, Jubilant Biosys is dedicated to assist in advancing the field of TF-targeted therapeutics. Custom-tailored screening platform that include below list of approaches.
- Ligand binding (Absorbance, Fluorescence).
- Probe displacement assay (HTRF).
- Bioluminescent Reporter assay (Luminescence).
- Target engagement (In-cell Thermal shift assay).
- Protein expression analysis (Jess, In-cell western, Traditional Western blotting).
- mRNA expression analysis (Realtime PCR).
- Protein-Protein interaction assays (Alpha-LISA, HTRF).
- Protein-Nucleotide interaction assays (Alpha-LISA, HTRF).
- Long term cell proliferation assays (CTG, RTG).
- Migration assay (Transwell chemotaxis, Invasion assay).
- Custom made phenotypic assays based on target biology.
Jubilan Biosys can support client projects at all stages of preclinical development ranging from protein production to preclinical candidate nomination. Medicinal chemistry strategies are driven by structure-based drug design using information provided by our in-house X-ray crystallographers.